PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12372041-3 2002 We reasoned therefore that the absence of IL-2R should permit lower doses of tacrolimus and thereby less toxicity. Tacrolimus 77-87 interleukin 2 receptor subunit alpha Homo sapiens 42-47 11053632-6 2000 Treatment with Tacr resulted in a decreased expression of costimulatory ligands and adhesion molecules (T cells: CD40L, p < 0.05; CD28 and CD54, p < or = 0.01; B cells: CD25, p = 0.05; CD40, p < 0.001; monocytes: CD40, p < 0.05), which coincided with decreased PHA-stimulated T cell IL-2 responses (398 +/- 153 versus 43 +/- 15 pg/ml, p < 0.05), impaired CD4 helper activity (117% +/- 22% versus 73% +/- 19%, p < 0.05) and increased CD4 suppressor activity (-120% +/- 28% versus -18% +/- 27%, p = 0.02). Tacrolimus 15-19 interleukin 2 receptor subunit alpha Homo sapiens 175-179 11174203-7 2001 Tacrolimus inhibited the expression of IL-2R (CD25) and of the costimulatory molecules CD80 (B7.1) and CD40. Tacrolimus 0-10 interleukin 2 receptor subunit alpha Homo sapiens 39-44 11174203-7 2001 Tacrolimus inhibited the expression of IL-2R (CD25) and of the costimulatory molecules CD80 (B7.1) and CD40. Tacrolimus 0-10 interleukin 2 receptor subunit alpha Homo sapiens 46-50 8557519-1 1995 We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin. Tacrolimus 230-240 interleukin 2 receptor subunit alpha Homo sapiens 56-78 8557519-2 1995 We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2. Tacrolimus 28-33 interleukin 2 receptor subunit alpha Homo sapiens 44-49 8557519-2 1995 We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2. Tacrolimus 28-33 interleukin 2 receptor subunit alpha Homo sapiens 51-55 8557519-1 1995 We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin. Tacrolimus 242-247 interleukin 2 receptor subunit alpha Homo sapiens 56-78 8137548-10 1994 Treatment with low-dose cyclosporin A (CsA) or FK506 in combination with BRC has proved more effective than either drug alone in suppression of T cell proliferation and CD25 antigen expression. Tacrolimus 47-52 interleukin 2 receptor subunit alpha Homo sapiens 169-173 1690915-9 1990 In contrast to corresponding PHA-stimulated cells, FK-506-treated alloactivated lymphocytes exhibited reductions in IL-2R, TR and HLA-DR antigen expression, which in the cases of IL-2R and TR were further reduced by combination of FK-506 with low-concentration CsA. Tacrolimus 51-57 interleukin 2 receptor subunit alpha Homo sapiens 116-121 7678231-14 1993 As reported for IL-2R and IL-4R, our data also show that the expression of another T cell growth factor receptor is sensitive to the effects of cyclosporin A and FK506. Tacrolimus 162-167 interleukin 2 receptor subunit alpha Homo sapiens 16-21 1281674-2 1992 Using Northern analyses and promoter-reporter constructs we analyzed the transcriptional and posttranscriptional effects of FK506 and rapamycin on IL-2, GM-CSF, and IL-2R alpha gene expression. Tacrolimus 124-129 interleukin 2 receptor subunit alpha Homo sapiens 165-176 1690915-9 1990 In contrast to corresponding PHA-stimulated cells, FK-506-treated alloactivated lymphocytes exhibited reductions in IL-2R, TR and HLA-DR antigen expression, which in the cases of IL-2R and TR were further reduced by combination of FK-506 with low-concentration CsA. Tacrolimus 51-57 interleukin 2 receptor subunit alpha Homo sapiens 179-184 34871120-12 2022 CONCLUSIONS: Reduced early tacrolimus exposure, facilitated by IL-2RA induction, was associated with reduced risk for HCC recurrence among patients outside Milan criteria. Tacrolimus 27-37 interleukin 2 receptor subunit alpha Homo sapiens 63-69 35143096-8 2022 CONCLUSIONS: Tacrolimus is the standard immunosuppression after LT and can be used in combination with other drugs such as corticosteroids and MMF, and in association with anti-IL2 receptor antibody (IL2Ra) induction. Tacrolimus 13-23 interleukin 2 receptor subunit alpha Homo sapiens 200-205 34335631-7 2021 In that group, absolute CD4+CD25+CD127-Foxp3+ Tregs were negatively associated with steroid dose and tacrolimus trough levels (r=-0.377, p = 0.021, n=37; r=-0.43, p=0.033, n=25, respectively), opposite to IL-10+ Bregs, whose frequency apparently was not negatively affected by potent immunosuppression early posttransplant. Tacrolimus 101-111 interleukin 2 receptor subunit alpha Homo sapiens 28-32 35143096-10 2022 Low dose or delayed introduction of tacrolimus in association with corticosteroids and MMF and/or anti-IL2Ra induction can be used to reduce acute kidney injury. Tacrolimus 36-46 interleukin 2 receptor subunit alpha Homo sapiens 103-108 33887727-0 2021 Outcomes of Interleukin-2 Receptor Antagonist Induction Therapy in Standard-Risk Renal Transplant Recipients Maintained on Tacrolimus: A Systematic Review and Meta-Analysis. Tacrolimus 123-133 interleukin 2 receptor subunit alpha Homo sapiens 12-45 28257599-7 2017 Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control. Tacrolimus 15-25 interleukin 2 receptor subunit alpha Homo sapiens 54-58 32170593-1 2020 BACKGROUND: The aim of this meta-analysis is to explore the effect of IL-2RA vs rATG on the rate of acute rejection, post-transplant infections, and graft as well as patient"s survival in standard- and high-risk renal transplant patients receiving tacrolimus-based maintenance immunotherapy. Tacrolimus 248-258 interleukin 2 receptor subunit alpha Homo sapiens 70-76 25979971-2 2015 However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids. Tacrolimus 57-67 interleukin 2 receptor subunit alpha Homo sapiens 16-22 16267794-6 2005 Current therapy tends to reduce steroid treatment doses and, optimizing induction therapy with IL-2R inhibitors, using tacrolimus or mycophenolate or sirolimus. Tacrolimus 119-129 interleukin 2 receptor subunit alpha Homo sapiens 95-100 20528886-8 2010 The rATG tacrolimus-induced CD25(+) T cells inhibited proliferative responses of alloantigen-stimulated effector T cells as vigorously as rATG-induced and natural CD4(+)CD25(+)FoxP3(+)CD127(-/low) T cells (67% +/- 18% versus 69% +/- 16% versus 45% +/- 20%, mean +/- standard error of the mean, respectively). Tacrolimus 9-19 interleukin 2 receptor subunit alpha Homo sapiens 28-32 20528886-8 2010 The rATG tacrolimus-induced CD25(+) T cells inhibited proliferative responses of alloantigen-stimulated effector T cells as vigorously as rATG-induced and natural CD4(+)CD25(+)FoxP3(+)CD127(-/low) T cells (67% +/- 18% versus 69% +/- 16% versus 45% +/- 20%, mean +/- standard error of the mean, respectively). Tacrolimus 9-19 interleukin 2 receptor subunit alpha Homo sapiens 169-173 20484893-8 2010 Statistically significant correlations between CD4+CD25(high)Foxp3+ Tregs and tacrolimus levels and CD4+CD25(high)Foxp3- Tregs and HLA-DR mismatching were detected. Tacrolimus 78-88 interleukin 2 receptor subunit alpha Homo sapiens 51-55 17889153-11 2007 The logistic regression analysis (dependent variable: PTDM; independent variables: age, anti-CD25, tacrolimus vs cyclosporine) showed that treatment with anti-CD25 is an independent risk factor for PTDM (P = .041; OR 3.28; CI 95% 1.04-10.31). Tacrolimus 99-109 interleukin 2 receptor subunit alpha Homo sapiens 159-163 16773453-5 2006 Tacrolimus treatment achieved a significant reduction of CD25+ cells. Tacrolimus 0-10 interleukin 2 receptor subunit alpha Homo sapiens 57-61 16400900-9 2005 CONCLUSIONS: We observed differential FK506 sensitivity of IL-15-driven CD25 up-regulation and apoptotic response comparing CB and APB T cells. Tacrolimus 38-43 interleukin 2 receptor subunit alpha Homo sapiens 72-76 25142246-8 2014 Moreover, strong and statistically significant associations were found between tacrolimus pharmacodynamic parameters and polymorphisms in the genes coding cyclophilin A, the calcineurin catalytic subunit alpha isoenzyme, and CD25. Tacrolimus 79-89 interleukin 2 receptor subunit alpha Homo sapiens 174-229 22863028-5 2012 Steroid-free tacrolimus monotherapy with rATG or IL-2RA induction is effective if adequate tacrolimus exposure is maintained. Tacrolimus 13-23 interleukin 2 receptor subunit alpha Homo sapiens 49-55 22863028-5 2012 Steroid-free tacrolimus monotherapy with rATG or IL-2RA induction is effective if adequate tacrolimus exposure is maintained. Tacrolimus 91-101 interleukin 2 receptor subunit alpha Homo sapiens 49-55 20671192-9 2010 Finally, FK506-treated NK cells showed impaired IL-2R signaling and inhibition of STAT3. Tacrolimus 9-14 interleukin 2 receptor subunit alpha Homo sapiens 48-53 19398001-1 2009 We evaluated whether the regulatory function of CD4(+)CD25(high+)FoxP3(+) T-cells from patients on tacrolimus and mycophenolate mofetil (MMF) is affected by preceding steroid and anti-CD25 mAb induction therapy and whether this function is associated with rejection after kidney transplantation. Tacrolimus 99-109 interleukin 2 receptor subunit alpha Homo sapiens 54-58 16054825-12 2005 The degree of donor leukocyte chimerism and the frequency of CD4+CD25+ T-cells were higher in the tacrolimus group, however, these differences were not statistically significant. Tacrolimus 98-108 interleukin 2 receptor subunit alpha Homo sapiens 65-69 12780674-0 2003 The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Tacrolimus 100-110 interleukin 2 receptor subunit alpha Homo sapiens 19-23 15866630-2 2005 Our purpose was to assess the safety and efficacy of an immunosuppressive regimen using anti-IL-2R antibodies and MMF that allows delayed introduction of low-dose tacrolimus using elderly donors to elderly recipients. Tacrolimus 163-173 interleukin 2 receptor subunit alpha Homo sapiens 93-98 12780674-2 2003 We examined the hypothesis that using anti-CD25 monoclonal antibody induction and mycophenolate mofetil (MMF) would allow the lowering of target pre-dose blood concentrations of tacrolimus immediately after transplantation and subsequently stopping steroids at 5 months. Tacrolimus 178-188 interleukin 2 receptor subunit alpha Homo sapiens 43-47 12780674-11 2003 CONCLUSION: A regimen consisting of anti-CD25 monoclonal antibody induction and MMF allows the safe and efficient use of low-target pre-dose trough concentrations of tacrolimus and enables the early discontinuation of steroids. Tacrolimus 166-176 interleukin 2 receptor subunit alpha Homo sapiens 41-45 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Tacrolimus 246-256 interleukin 2 receptor subunit alpha Homo sapiens 4-9